ClinicalTrials.gov
ClinicalTrials.gov Menu

Antidiabetic Properties of Rose Hip

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01316016
Recruitment Status : Completed
First Posted : March 16, 2011
Last Update Posted : March 16, 2011
Sponsor:
Information provided by:
Lund University

Brief Summary:
The purpose of this study is to determine whether daily intake of a drink containing rose hip powder reduces risk markers of type diabetes and cardiovascular disease.

Condition or disease Intervention/treatment Phase
Obesity Dietary Supplement: Rose hip Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Rose Hip Intake on Risk Markers of Type 2 Diabetes and Cardiovascular Disease: a Randomized Double-blind Cross-over Investigation in Obese Persons
Study Start Date : April 2009
Actual Primary Completion Date : February 2010
Actual Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Rose hip Dietary Supplement: Rose hip
40 g of rose hip powder daily for 6 weeks.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • BMI > 30
  • willingness to participate in the study
  • willingness to comply with the daily intake of drinks and the recommended energy intake during the course of the study

Exclusion Criteria:

  • diabetes
  • previous or ongoing insulin treatment
  • abnormal thyroid status
  • abnormal liver status
  • abnormal kidney status
  • known gastrointestinal disorder
  • pregnancy
  • suspected allergy to ingredients of the drinks

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01316016


Locations
Sweden
Endocrinology Clinic, Lund University Hospital
Lund, Sweden, SE-22185
Sponsors and Collaborators
Lund University
Investigators
Study Chair: Per Katzman, MD/PhD Lund University

Publications:
Responsible Party: Cecilia Holm, Lund University
ClinicalTrials.gov Identifier: NCT01316016     History of Changes
Other Study ID Numbers: LUAFC002
First Posted: March 16, 2011    Key Record Dates
Last Update Posted: March 16, 2011
Last Verified: February 2011

Keywords provided by Lund University:
obesity
glucose intolerance
cholesterol
blood pressure